Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

McMaster University

$105,000.00

Investigating the impact of polyglutamine expansion on the DNA damage response of ataxin-1 in the context of spinocerebellar ataxia type 1

FY 2019-20

Summary
Spinocerebellar ataxia type 1 (SCA1) is a neurodegenerative disease caused by a mutation in the ATXN1 gene. Patients first begin to lose their balance and motor control, followed by difficulty speaking and swallowing food, and then cognitive decline. Symptoms begin in a person's thirties or forties, after which life expectancy is 10-15 years. There are no treatments available for SCA1. SCA1 is part of the polyglutamine expansion disease family, along with the more common Huntington's Disease (HD). This means that the mutation in the ATXN1 gene causes repetition of the amino acid glutamine in the ataxin-1 protein. We do not fully understand what function the ataxin-1 protein has in the body. We do know that these glutamine repeats cause problems which leads to SCA1. Recent studies have suggested that the proteins affected in HD and SCA1 may be involved in DNA damage repair. We have shown that that ataxin-1 goes to sites of DNA damage following stress events, and that the disease version of the protein is worse at going to damage. Our current project has three main goals. First, understanding what role ataxin-1 has at DNA damage. Second, figuring out how disruption of this function contributes to SCA1 disease symptoms. Third, identify how ataxin-1 travels to damage and how this is impacted by polyglutamine expansion. If we can identify a difference between the normal and disease protein during DNA repair, this would be the first step in developing a potential treatment for SCA1. We are figuring out what the function of the protein is, and how it is changed in disease. If we answer that question, we could then focus on how to fix the problem and make the disease protein act like the normal protein. That research is far in the future, but it will not happen unless we lay the groundwork with projects such as this one. Since HD and SCA1 are so similar, a discovery in SCA1 could help with HD research.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
416734
Name
Suart Celeste
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the impact of polyglutamine expansion on the DNA damage response of ataxin-1 in the context of spinocerebellar ataxia type 1
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Ataxia; Cag Triplet Repeat Disorder; Cell Biology; Dna Damage; Microscopy; Neurodegeneration; Polyglutamine Expansion Disease; Spinocerebellar Ataxia Type 1
Abstract
Spinocerebellar ataxia type 1 (SCA1) is a neurodegenerative disease caused by a mutation in the ATXN1 gene. Patients first begin to lose their balance and motor control, followed by difficulty speaking and swallowing food, and then cognitive decline. Symptoms begin in a person's thirties or forties, after which life expectancy is 10-15 years. There are no treatments available for SCA1. SCA1 is part of the polyglutamine expansion disease family, along with the more common Huntington's Disease (HD). This means that the mutation in the ATXN1 gene causes repetition of the amino acid glutamine in the ataxin-1 protein. We do not fully understand what function the ataxin-1 protein has in the body. We do know that these glutamine repeats cause problems which leads to SCA1. Recent studies have suggested that the proteins affected in HD and SCA1 may be involved in DNA damage repair. We have shown that that ataxin-1 goes to sites of DNA damage following stress events, and that the disease version of the protein is worse at going to damage. Our current project has three main goals. First, understanding what role ataxin-1 has at DNA damage. Second, figuring out how disruption of this function contributes to SCA1 disease symptoms. Third, identify how ataxin-1 travels to damage and how this is impacted by polyglutamine expansion. If we can identify a difference between the normal and disease protein during DNA repair, this would be the first step in developing a potential treatment for SCA1. We are figuring out what the function of the protein is, and how it is changed in disease. If we answer that question, we could then focus on how to fix the problem and make the disease protein act like the normal protein. That research is far in the future, but it will not happen unless we lay the groundwork with projects such as this one. Since HD and SCA1 are so similar, a discovery in SCA1 could help with HD research.
Competitiondate
201911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Suart, Celeste
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McMaster University - $105,000 Grant (2019-20) | Canada Spends